Effects of SGLT-2 inhibitor on appetite, food craving, and body weight

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0009925

Enrollment

Registered

2024-11-13

Start date

2017-02-22

Completion date

Unknown

Last updated

2024-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Clinical trial participants will be randomly assigned to either the experimental group (SGLT-2 inhibitor group) or the active control group (DPP-4 inhibitor group) and will take dapagliflozin 1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Type 2 diabetes patients - Age 20 years or older and 70 years or younger - Fasting blood glucose = 130 mg/dl, postprandial blood glucose = 180 mg/dl, or HbA1c = 6.5% - BMI = 20 kg/m2 - Patients with preserved renal function (eGFR = 60 ml/min/1.73 m2) - Those who agree to participate in this study

Exclusion criteria

Exclusion criteria: - Type 1 diabetes, gestational diabetes, and other secondary diabetes (e.g., diabetes after pancreatectomy, diabetes due to steroid use, etc.) - Under 20 years of age, over 70 years of age - If there has been a change in diabetes treatment medication within the past month - If SGLT-2 inhibitor or DPP-IV inhibitor has been administered within the past month - BMI <20 kg/m2 - Patients with impaired renal function (eGFR <60 ml/min/1.73 m2) - If there is a malignancy, severe infection, severe renal/liver disease, chronic pancreatitis, alcohol dependence, etc. - If there is a history of recurrent urinary tract infections - If taking medication for weight control or participating in a weight control program - If taking loop diuretics

Design outcomes

Primary

Measure	Time frame
The difference in weight loss (kg) between the experimental group and the control group at week 24 compared to baseline.	—

Secondary

Measure	Time frame
The proportion of participants with HbA1c <6.5% at week 24.;The changes in HbA1c, FBS, lipid profile, ketone levels, and BP from baseline to week 24.; The changes in appetite-related hormones (leptin, peptide YY, neuropeptide Y, GLP-1 total) from baseline to week 24.; The changes in dietary behavior and food craving scores from baseline to week 24.; The changes in total daily energy expenditure and carbohydrate intake from baseline to week 24.	—

Measure

Time frame

The proportion of participants with HbA1c <6.5% at week 24.;The changes in HbA1c, FBS, lipid profile, ketone levels, and BP from baseline to week 24.; The changes in appetite-related hormones (leptin, peptide YY, neuropeptide Y, GLP-1 total) from baseline to week 24.; The changes in dietary behavior and food craving scores from baseline to week 24.; The changes in total daily energy expenditure and carbohydrate intake from baseline to week 24.

—

Countries

Korea, Republic of

Contacts

Public ContactEun Young Lee

The Catholic University of Korea, Seoul St. Mary's Hospital

leyme@catholic.ac.kr+82-2-2258-6274

Outcome results